ReachMD

Be part of the knowledge.™

Oncology - Hematology

70

LikeLikedUnlike

Episodes 1-15 of 32

- S. Michelle Shiller, DO, AP/CP, MGP
  Peer
- John V. Heymach, MD, PhD
  Peer
0
Medical Industry Feature
Spotlight on the Rare & Challenging EGFR Exon 20 Insertion in NSCLC
Spotlight on the Rare & Challenging EGFR Exon 20 Insertion in NSCLC
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Noa Biran, MD
  Peer
0
Medical Industry Feature
5-Year Follow-Up Update of the MAIA Study
5-Year Follow-Up Update of the MAIA Study
- Bradley J. Monk, MD, FACS, FACOG
  Peer
- Leslie Randall, MD, MAS
  Peer
0
Medical Industry Feature
An Overview of the Epidemiology of Cervical Cancer
An Overview of the Epidemiology of Cervical Cancer
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Arielle Heeke, MD
  Peer
2
Medical Industry Feature
Key Considerations for G-CSF Administration in Patients with FN Risk
Key Considerations for G-CSF Administration in Patients with FN Risk
- Azra Raza, MD
  Peer
- Rami Komrokji, MD
  Peer
0
Medical Industry Feature
Examining the Evolving MDS Treatment Landscape in Today’s Climate
Examining the Evolving MDS Treatment Landscape in Today’s Climate
- Jennifer Caudle, DO
  Peer
- Mark Socinski, MD
  Peer
5
Medical Industry Feature
An Expert Interview for 2L SCLC: A Look Into the Patient Journey
An Expert Interview for 2L SCLC: A Look Into the Patient Journey
- Rami Komrokji, MD
  Peer
- Natasha Johnson, MSN, APRN, AOCNP
  Peer
0
Medical Industry Feature
Treating MDS: A Look at an Approved Treatment
Treating MDS: A Look at an Approved Treatment
- Ashley Moncrief, RN, BSN
  Peer
- Natasha Johnson, MSN, APRN, AOCNP
  Peer
0
Medical Industry Feature
A Look at the Treatment Journey & Patient Experience for MDS
A Look at the Treatment Journey & Patient Experience for MDS
- Roy Decker, MD, PhD
  Peer
0
Broadcast Replay
Understanding Unresectable Stage III NSCLC: A Radiation Oncologist’s Perspective
Understanding Unresectable Stage III NSCLC: A Radiation Oncologist’s Perspective
- Amit G. Singal, MD, MS
  Peer
1
Medical Industry Feature
HCC Surveillance: Evaluating Evolving Data & Impacts on Outcomes
HCC Surveillance: Evaluating Evolving Data & Impacts on Outcomes
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Jerome Goldschmidt, MD
  Peer
1
Medical Industry Feature
Integrating Real-World Evidence into Oncology Practice: A Closer Look at Biosimilars
Integrating Real-World Evidence into Oncology Practice: A Closer Look at Biosimilars
0
Medical Industry Feature
Review Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
Review Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma
- Grace Cherry, RN, MSN, NP
  Peer
- Suzanne McGettigan, MSN
  Peer
0
Medical Industry Feature
Guidance for Initiating a Targeted Combination Treatment for BRAF Mutation-Positive Stage III or Advanced Melanoma
Guidance for Initiating a Targeted Combination Treatment for BRAF Mutation-Positive Stage III or Advanced Melanoma
- Jennifer Caudle, DO
  Peer
- Joseph Mikhael, MD
  Peer
0
Medical Industry Feature
Viewpoint on CANDOR: A Unique Combination for Patients With Multiple Myeloma at First Relapse
Viewpoint on CANDOR: A Unique Combination for Patients With Multiple Myeloma at First Relapse
- Jennifer Caudle, DO
  Peer
- Keith McCrae, MD
  Peer
3
Medical Industry Feature
Key Recommendations for ITP: Updates on Management & Treatment from the 2019 ASH Guidelines
Key Recommendations for ITP: Updates on Management & Treatment from the 2019 ASH Guidelines

Segment Chapters

Playlist:

Recommended

Webpack App